Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

(Reuters) -The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory-robbing disease.

At a time when global coordination against health threats is critical, recent policy shifts in the U.S. have created a ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals ... The collaboration agreement centres around Alchemab’s antibody discovery platform, which uses patient samples from those with ...

These are some of the areas where Eli Lilly, flush with cash from its GLP ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory ...

The peptides activate receptors of a gut hormone called GLP-1, while the antibody blocks receptors of another hormone called GIP. That's unlike Eli Lilly's obesity drug, Zepbound, which activates ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...